The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population

Linda Abetz, Robert Arbuckle, Richard Allen, Elena Mavraki, Jeffrey Kirsch

Research output: Contribution to journalArticle

Abstract

Background: The aim of this study was to determine the reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a clinical trial selling. Methods: Two matching, placebo-controlled, multinational studies assessing the effectiveness and safety of ropinirole for treating moderate-to-severe Restless Legs Syndrome (RLS) formed the basis of this psychometric assessment. Validity and reliability were assessed using baseline data. Responsiveness was determined using longitudinal data collected at baseline and 12 weeks. Results: A total of 547 subjects formed the baseline validation population; 519 were used for assessing responsiveness (n = 284/263 and 271/248 for both studies, respectively). Construct validity assessment confirmed that an overall life impact score could be calculated. All item-scale correlations were ≥ 0.4, except items 1 (r = 0.36) and 5 (r = 0.35) in one study. Floor and ceiling effects were minimal. Cronbach's alpha values were 0.82 and 0.87, respectively, confirming internal consistency reliability. Correlations with the International Restless Legs Syndrome Study Group's severity rating scale (International Restless Legs Scale; IRLS) were moderate (r = -0.68 and -0.67, respectively; p <0.0001). The RLSQoL was able to discriminate between levels of sleep problems (p

Original languageEnglish (US)
Article number79
JournalHealth and Quality of Life Outcomes
Volume3
DOIs
StatePublished - Dec 5 2005

Fingerprint

Restless Legs Syndrome
Reproducibility of Results
Quality of Life
Population
Psychometrics
Sleep
Placebos
Surveys and Questionnaires
Clinical Trials
Safety

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population. / Abetz, Linda; Arbuckle, Robert; Allen, Richard; Mavraki, Elena; Kirsch, Jeffrey.

In: Health and Quality of Life Outcomes, Vol. 3, 79, 05.12.2005.

Research output: Contribution to journalArticle

@article{b7cdab7171ad4305ac643e31446ec1ad,
title = "The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population",
abstract = "Background: The aim of this study was to determine the reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a clinical trial selling. Methods: Two matching, placebo-controlled, multinational studies assessing the effectiveness and safety of ropinirole for treating moderate-to-severe Restless Legs Syndrome (RLS) formed the basis of this psychometric assessment. Validity and reliability were assessed using baseline data. Responsiveness was determined using longitudinal data collected at baseline and 12 weeks. Results: A total of 547 subjects formed the baseline validation population; 519 were used for assessing responsiveness (n = 284/263 and 271/248 for both studies, respectively). Construct validity assessment confirmed that an overall life impact score could be calculated. All item-scale correlations were ≥ 0.4, except items 1 (r = 0.36) and 5 (r = 0.35) in one study. Floor and ceiling effects were minimal. Cronbach's alpha values were 0.82 and 0.87, respectively, confirming internal consistency reliability. Correlations with the International Restless Legs Syndrome Study Group's severity rating scale (International Restless Legs Scale; IRLS) were moderate (r = -0.68 and -0.67, respectively; p <0.0001). The RLSQoL was able to discriminate between levels of sleep problems (p",
author = "Linda Abetz and Robert Arbuckle and Richard Allen and Elena Mavraki and Jeffrey Kirsch",
year = "2005",
month = "12",
day = "5",
doi = "10.1186/1477-7525-3-79",
language = "English (US)",
volume = "3",
journal = "Health and Quality of Life Outcomes",
issn = "1477-7525",
publisher = "BioMed Central",

}

TY - JOUR

T1 - The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population

AU - Abetz, Linda

AU - Arbuckle, Robert

AU - Allen, Richard

AU - Mavraki, Elena

AU - Kirsch, Jeffrey

PY - 2005/12/5

Y1 - 2005/12/5

N2 - Background: The aim of this study was to determine the reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a clinical trial selling. Methods: Two matching, placebo-controlled, multinational studies assessing the effectiveness and safety of ropinirole for treating moderate-to-severe Restless Legs Syndrome (RLS) formed the basis of this psychometric assessment. Validity and reliability were assessed using baseline data. Responsiveness was determined using longitudinal data collected at baseline and 12 weeks. Results: A total of 547 subjects formed the baseline validation population; 519 were used for assessing responsiveness (n = 284/263 and 271/248 for both studies, respectively). Construct validity assessment confirmed that an overall life impact score could be calculated. All item-scale correlations were ≥ 0.4, except items 1 (r = 0.36) and 5 (r = 0.35) in one study. Floor and ceiling effects were minimal. Cronbach's alpha values were 0.82 and 0.87, respectively, confirming internal consistency reliability. Correlations with the International Restless Legs Syndrome Study Group's severity rating scale (International Restless Legs Scale; IRLS) were moderate (r = -0.68 and -0.67, respectively; p <0.0001). The RLSQoL was able to discriminate between levels of sleep problems (p

AB - Background: The aim of this study was to determine the reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a clinical trial selling. Methods: Two matching, placebo-controlled, multinational studies assessing the effectiveness and safety of ropinirole for treating moderate-to-severe Restless Legs Syndrome (RLS) formed the basis of this psychometric assessment. Validity and reliability were assessed using baseline data. Responsiveness was determined using longitudinal data collected at baseline and 12 weeks. Results: A total of 547 subjects formed the baseline validation population; 519 were used for assessing responsiveness (n = 284/263 and 271/248 for both studies, respectively). Construct validity assessment confirmed that an overall life impact score could be calculated. All item-scale correlations were ≥ 0.4, except items 1 (r = 0.36) and 5 (r = 0.35) in one study. Floor and ceiling effects were minimal. Cronbach's alpha values were 0.82 and 0.87, respectively, confirming internal consistency reliability. Correlations with the International Restless Legs Syndrome Study Group's severity rating scale (International Restless Legs Scale; IRLS) were moderate (r = -0.68 and -0.67, respectively; p <0.0001). The RLSQoL was able to discriminate between levels of sleep problems (p

UR - http://www.scopus.com/inward/record.url?scp=29144508513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144508513&partnerID=8YFLogxK

U2 - 10.1186/1477-7525-3-79

DO - 10.1186/1477-7525-3-79

M3 - Article

C2 - 16329756

AN - SCOPUS:29144508513

VL - 3

JO - Health and Quality of Life Outcomes

JF - Health and Quality of Life Outcomes

SN - 1477-7525

M1 - 79

ER -